Ogi M, Iwase N, Kitamura T, Sawanobori T, Fujimaki S, Kuramochi M, Fujita T, Yokoyama H, Tomosugi N, Takabatake T
Department of Internal Medicine, Tohsei National Hospital, Shizuoka, Japan.
Nihon Jinzo Gakkai Shi. 1993 Feb;35(2):161-70.
Risk factors for contrast nephropathy were prospectively studied in 17 patients with non-insulin dependent diabetes mellitus undergoing cardioangiography. Contrast nephropathy, defined as a serum creatinine increase of greater than 25% at 3 day after angiography, occurred in 29.4% of diabetic patients. Patients who developed contrast nephropathy had significantly higher serum creatinine (Cr), fractional excretion of sodium (FENa), urinary albumin excretion rate (AER), and lower 24hr Ccr than patients who did not (Cr: 1.5 +/- 0.3 mg/dl vs. 0.8 +/- 0.1 mg/dl, FENa: 1.9 +/- 0.5% vs. 0.6 +/- 0.1%, AER: 522 +/- 335 micrograms/min vs. 27 +/- 13 micrograms/min, 24hr Ccr: 39.1 +/- 11.6 ml/min vs. 86.2 +/- 9.3 ml/min, P < 0.05). Contrast nephropathy developed in all of two patients with overt proteinuria (AER more than 200 micrograms/min), but none of eight patients with normoalbuminuria (AER below 15 micrograms/min). Three of seven patients with microalbuminuria developed contrast nephropathy, and two of them had advanced nephropathy. FENa obtained next day was significantly elevated over baseline in patients with contrast nephropathy (1.9 +/- 0.5% vs. 9.7 +/- 4.5%, P < 0.05), but unchanged in patients without contrast nephropathy. The rise in C beta 2-microglobulin/Ccr and enzymuria was noted in both group. Percentage decrease of Ccr on the next day was positively correlated with FENa before angiography (r = 0.645, p < 0.01). Of 24hr Ccr, AER, and FENa before angiography, FENa was revealed as a statistically significant discriminant factor for contrast nephropathy by stepwise discriminant analysis (p = 0.0008). These results suggest that contrast nephropathy develops predominantly in the stage not of incipient but of overt diabetic nephropathy indicated by a decline of glomerular filtration, overt proteinuria, and tubular dysfunction. Of them, tubular dysfunction may be the most important risk factor for contrast nephropathy.
对17例接受心血管造影术的非胰岛素依赖型糖尿病患者进行了对比剂肾病危险因素的前瞻性研究。对比剂肾病定义为造影术后3天血清肌酐升高超过25%,在29.4%的糖尿病患者中发生。发生对比剂肾病的患者比未发生的患者血清肌酐(Cr)、钠分数排泄率(FENa)、尿白蛋白排泄率(AER)显著更高,而24小时肌酐清除率(Ccr)更低(Cr:1.5±0.3mg/dl对0.8±0.1mg/dl,FENa:1.9±0.5%对0.6±0.1%,AER:522±335μg/min对27±13μg/min,24小时Ccr:39.1±11.6ml/min对86.2±9.3ml/min,P<0.05)。所有2例显性蛋白尿(AER超过200μg/min)患者均发生了对比剂肾病,但8例正常白蛋白尿(AER低于15μg/min)患者均未发生。7例微量白蛋白尿患者中有3例发生了对比剂肾病,其中2例患有晚期肾病。发生对比剂肾病患者第二天的FENa较基线显著升高(1.9±0.5%对9.7±4.5%,P<0.05),而未发生对比剂肾病患者则无变化。两组均观察到Cβ2-微球蛋白/Ccr和酶尿的升高。第二天Ccr的下降百分比与造影术前的FENa呈正相关(r=0.645,p<0.01)。通过逐步判别分析,造影术前的24小时Ccr、AER和FENa中,FENa被揭示为对比剂肾病的统计学显著判别因素(p=0.0008)。这些结果表明,对比剂肾病主要发生在糖尿病肾病的非早期而是显性期,表现为肾小球滤过率下降、显性蛋白尿和肾小管功能障碍。其中,肾小管功能障碍可能是对比剂肾病最重要的危险因素。